Current Report Filing (8-k)
December 15 2016 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
December 15, 2016
Date of Report (Date of earliest event reported)
AEVI GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.03. Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
Effective at 12:01
a.m. Eastern Time on December 15, 2016, Medgenics, Inc. (the “
Company
”) changed its name to “Aevi
Genomic Medicine, Inc.” by filing a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation
with the Secretary of State of the State of Delaware (the “
Certificate of Amendment
”). The amendment
was effected pursuant to Section 242 of the Delaware General Corporation Law, which permits such amendments to be adopted by a
corporation’s board of directors without stockholder approval. The name change does not affect the rights of the Company’s
security holders. There were no other changes to the Company’s Amended and Restated Certificate of Incorporation in connection
with the amendment.
The Company also
amended and restated its Second Amended and Restated By-Laws (as so amended and restated, the “
Third Amended and
Restated By-Laws
”) solely to reflect the corporate name change. The amendment and restatement of the
Second Amended and Restated By-Laws, also effective as of December 15, 2016, does not affect the current rights of the
Company’s security holders.
Effective
December 16, 2016, the Company’s common stock, which trades on the Nasdaq Global Market, will cease trading under the
ticker symbol “MDGN” and will commence trading under the new ticker symbol “GNMX”. Along with the
ticker change, the Company’s common stock has also been assigned a new CUSIP number of 00835P105. Outstanding
certificates for shares of the Company’s common stock will continue to be valid and need not be exchanged.
On December 15, 2016,
the Company announced the name and ticker symbol change via a press release. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference into this Item 5.03.
The foregoing description
of the Certificate of Amendment and the Third Amended and Restated By-Laws does not purport to be complete and is qualified in
its entirety by reference to the full text of the Certificate of Amendment and the Third Amended and Restated By-Laws, copies of
which are filed as Exhibits 3.1 and 3.2 hereto, respectively, and incorporated by reference herein.
Item 8.01. Other Events.
The information under
Item 5.03 regarding the change to the Company’s ticker symbol change is incorporated herein by reference into this Item 8.01.
Item 9.01. Financial Statements and Exhibits.
(d)
|
Exhibits
|
|
|
|
|
|
Exhibit Number
|
Exhibit
|
|
|
|
|
3.1
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Medgenics, Inc., effective as of December 15, 2016.
|
|
|
|
|
3.2
|
Third Amended and Restated By-Laws of Aevi Genomic Medicine, Inc., effective as of December 15, 2016.
|
|
|
|
|
99.1
|
Aevi Genomic Medicine, Inc. Press Release dated December 15, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Brian D. Piper
|
|
|
|
Name: Brian D. Piper
|
|
|
|
Title: Chief Financial Officer
|
|
Date: December 15, 2016
Item 9.01. Financial Statements and Exhibits.
|
Exhibit Number
|
Exhibit
|
|
|
|
|
3.1
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Medgenics, Inc., effective as of December 15, 2016.
|
|
|
|
|
3.2
|
Third Amended and Restated By-Laws of Aevi Genomic Medicine, Inc., effective as of December 15, 2016.
|
|
|
|
|
99.1
|
Aevi Genomic Medicine, Inc. Press Release dated December 15, 2016.
|
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jul 2023 to Jul 2024